GlassScriptPhysician profile
David Bencie
NPI 1720070436
$16,140.81
in general payments reported to CMS, 2019-2025
50 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,309 · 2020: $1,797 · 2021: $2,710 · 2022: $2,206 · 2023: $2,095 · 2024: $2,636 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,906 · Travel and Lodging: $192 · Education: $21.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,905.86 |
| Travel and Lodging | $191.81 |
| Education | $21.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,994.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,613.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,605.29 | 2019-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,062.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $911.87 | 2019-2025 | Kisunla, Jardiance, Mounjaro |
| Amarin Pharma, INC. | $886.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $853.63 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $799.15 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boston Scientific Corporation | $723.54 | 2022-2025 | Watchman Flx, Watchman, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.87 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $517.94 | 2020-2024 | Opdivo, Eliquis |
| Sanofi-Aventis U.S. LLC | $468.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $354.00 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $320.91 | 2019-2024 | Tezspire, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.61 | 2022-2025 | Xifaxan, Trulance |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $267.21 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $264.96 | 2021 | |
| Phathom Pharmaceuticals, INC. | $259.77 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $234.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $208.81 | 2023-2025 | Rexulti |
| Allergan, INC. | $154.82 | 2019-2020 | |
| Astellas Pharma US INC | $148.06 | 2019-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $142.41 | 2022 | |
| Inari Medical, INC. | $131.59 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Eisai INC. | $112.62 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $112.50 | 2024-2025 | Zenpep |
| Lundbeck LLC | $103.91 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $102.49 | 2020-2021 | |
| Daiichi Sankyo INC. | $100.74 | 2022-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $95.95 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.08 | 2024 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $55.48 | 2019-2021 | |
| Biogen, INC. | $49.75 | 2021-2022 | |
| Abiomed | $42.39 | 2025 | |
| Alexion Pharmaceuticals, INC. | $40.97 | 2023-2025 | Ultomiris |
| Abbott Laboratories | $39.89 | 2023-2024 | Freestyle Libre 3 |
| Stryker Corporation | $35.45 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dexcom, INC. | $32.97 | 2022-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $21.04 | 2023 | Afrezza |
| Verona Pharma, INC. | $20.90 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $20.13 | 2023 | Accrufer |
| Tactile Systems Technology INC | $19.29 | 2024 | Entre Plus, Flexitouch Plus |
| Xeris Pharmaceuticals, INC. | $19.26 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $18.94 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $17.86 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $17.32 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.62 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $13.91 | 2024 | Nuplazid |
| Sanofi Pasteur INC. | $12.92 | 2022 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bencie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.